Business Wire

Hopin Acquires StreamYard, a Leading Live Video Streaming Studio, for $250 Million

7.1.2021 15:30:00 EET | Business Wire | Press release

Share

Hopin, a leading virtual events platform, announced today that it has acquired StreamYard, a live video streaming studio that allows content creators to produce professional-quality video streaming experiences. The purchase will allow Hopin to provide advanced video production features to Hopin event organizers. In addition to eventually integrating its features into the Hopin platform, StreamYard will continue to also offer its live streaming studio tools to independent content creators. Hopin will pay a total purchase consideration of $250 million to acquire StreamYard, comprised of cash and stock.

“When I founded Hopin, I wanted to replicate all the best aspects of physical events -- from one-on-one networking to exploring an expo -- and more. As Hopin became the go-to virtual venue for event organizers, the next product to add was professional-quality video production, so I’ve long had my eye on the advanced studio tools that StreamYard provides,” said Johnny Boufarhat, founder and CEO of Hopin. “StreamYard is the solution of choice for live streamers around the world because of its superior ease of use and great features. This acquisition fits in with our goal to build the best products that help people connect and communicate better through engaging online experiences. I can’t wait to make it available to all of our customers so they can uplevel their events and truly dazzle their attendees.”

“Live streamers love StreamYard for its ease of use, stability, and professional-quality streams and I am thrilled that we can now easily bring those three pillars to event organizers around the world,” said Geige Vandentop, co-founder and CEO, StreamYard. “We have been integrating with Hopin as a third-party broadcast solution for months and it just makes sense to officially join forces and combine our efforts. At StreamYard, we are now committed to serving the needs of content creators and event producers alike.”

StreamYard, based in Tualatin, Oregon, was founded in 2018 by Geige Vandentop and Dan Briggs. They were inspired by live streaming’s rapid growth in the gaming community, which ultimately allowed people to turn hobbies into careers. However, they recognized that live streaming production required expensive hardware and an understanding of complex technology, a considerable barrier for most businesses wanting to create compelling live content for their audiences. To solve this, they developed a streaming solution that was simple to use by anyone, but powerful enough to create professional-quality content. The two founders bootstrapped StreamYard and grew revenues to nearly $10 million in early 2020 before quickly hiring a team of 19 and reaching over $30 million in annual recurring revenue by year-end. Today, StreamYard serves over 100,000 paying customers, adding 10,000 paying customers per month, and powers millions of broadcasts every month with a diverse global user-base ranging from social media influencers to large corporations.

StreamYard is a cloud-based solution that works in any web browser to empower businesses, entertainers, hobbyists, nonprofits, and anyone with a message to create compelling live events for their audiences and simulcast live to a number of social channels, including YouTube, Facebook, LinkedIn, and Twitch. It allows creators to easily brand their broadcasts with themes, color schemes, overlays, backgrounds, logos, and even GIFs. They can also easily host up to ten live guests to interview at once, show on-screen comments from viewers, and add call-to-action interactions to increase conversions and sales.

Hopin and StreamYard will work together to help event organizers bring StreamYard’s compelling, engaging, and easy-to-use capabilities to their online gatherings. StreamYard will soon replace the Hopin Studio and power all Hopin Stages, with native integration expected in H1 2021. Hopin aims to accelerate StreamYard’s innovative product development, sales and marketing, and grow StreamYard’s enterprise customer base. Vandentop and Briggs will continue to oversee the StreamYard team of 19 employees, while joining Hopin to assist Boufarhat in building out the company’s overall vision as a one-stop-shop for the best video broadcasting services and virtual event experiences.

“Hopin is one of our most astounding growth stories; the team’s Series B in November was a momentous milestone in every respect, including for the fast-changing virtual events industry,” said Sonali De Rycker, partner at Accel. “And they’ve now acquired two companies—first Topi, and now StreamYard. To pull this off in the first year of operation is unprecedented. The combination with StreamYard is incredibly powerful and will further fuel Hopin’s trajectory as it charts the future of online experiences.”

Hopin continues to enjoy rapid growth and soaring demand since its launch in February 2020. It has scaled from 5,000 registered users and 1,800 organizations hosting events on the Hopin platform to more than 5 million users and over 100,000 organizations hosting events. Last year alone, the remote-first company grew from eight employees to nearly 300 across 38 countries. Hopin has raised over $170 million to date, most recently completing a $125 million Series B led by IVP and Tiger Global and joined by Coatue and DFJ Growth, along with Hopin’s returning investors Accel, Northzone, Salesforce Ventures, and Seedcamp.

About Hopin

Founded in 2019, Hopin is the first all-in-one live virtual events platform where attendees can learn, interact, and connect with people from anywhere in the world. With Hopin, you can create live virtual and hybrid events that are interactive and immersive. Whether you're hosting a live training workshop, bringing your company’s remote team together, or launching a full-scale annual conference, it’s easy to create an engaging event on Hopin for up to hundreds of thousands of people. Attendees can network one-on-one, break out into group sessions, watch keynote presentations, send chat messages and polls, and explore interactive expo areas. There’s also a virtual backstage for speakers and plenty of sponsorship opportunities. Hopin is a remote-first company based in London, with employees in 38 countries. Learn more at hopin.com.

About StreamYard

StreamYard provides a live video streaming studio that allows content creators to produce professional-quality streaming experiences. StreamYard’s cloud-based solution makes it easy to create graphically-rich branded experiences, host multiple guests at once, engage with viewers, and simulcast to multiple live streaming platforms, including YouTube, Facebook, LinkedIn, and Twitch. Founded in 2018, StreamYard is based in Tualatin, Oregon. For more information, visit streamyard.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hopin
Niko Felix
niko@theoutcastagency.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye